US OptionsDetailed Quotes
VTYX250117P2500
- 0.30
- 0.000.00%
15min DelayTrading Jan 8 12:27 ET
0.00High0.00Low
0.00Open0.30Pre Close0 Volume439 Open Interest2.50Strike Price0.00Turnover120.63%IV-3.04%PremiumJan 17, 2025Expiry Date0.37Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8019Delta0.7768Gamma5.34Leverage Ratio-0.0068Theta-0.0004Rho-4.28Eff Leverage0.0008Vega
Ventyx Biosciences Stock Discussion
Sign in to post a comment
Columns Pay me
Here have some gifts, my weekend work so far:
$Yalla (YALA.US)$ diversity outside Asia/us, expanding reach
$NexGel (NXGL.US)$ specialized medical applications will see higher demand as the saline shortage goes on, and more look to alternatives
$Lumen Technologies (LUMN.US)$ ongoing transitions, personally see an increase in presence (which is impressive, honestly, I'm a nobody in random town), and they are approaching good buy levels
$Rezolute (RZLT.US)$ also approaching oversold
$Ventyx Biosciences (VTYX.US)$ impressiv...
$Yalla (YALA.US)$ diversity outside Asia/us, expanding reach
$NexGel (NXGL.US)$ specialized medical applications will see higher demand as the saline shortage goes on, and more look to alternatives
$Lumen Technologies (LUMN.US)$ ongoing transitions, personally see an increase in presence (which is impressive, honestly, I'm a nobody in random town), and they are approaching good buy levels
$Rezolute (RZLT.US)$ also approaching oversold
$Ventyx Biosciences (VTYX.US)$ impressiv...
4
1
$Ventyx Biosciences (VTYX.US)$
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
Ventyx Biosciences (Nasdaq: VTYX) presented new 52-week results from the Phase 2 trial of VTX002 (tamuzimod) in ulcerative colitis at UEG Week 2024. The late-breaking abstract highlighted high rates of clinical and endoscopic remission among long-term extension (LTE) completers at Week 52. CEO Raju Mohan emphasized the data's reinfo...
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
Ventyx Biosciences (Nasdaq: VTYX) presented new 52-week results from the Phase 2 trial of VTX002 (tamuzimod) in ulcerative colitis at UEG Week 2024. The late-breaking abstract highlighted high rates of clinical and endoscopic remission among long-term extension (LTE) completers at Week 52. CEO Raju Mohan emphasized the data's reinfo...
$Ventyx Biosciences (VTYX.US)$
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price...
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price...
$Ventyx Biosciences (VTYX.US)$ Reuters· just
Ventyx Biosciences Announces $27 Million Strategic Investment From Sanofi
Ventyx Biosciences Announces $27 Million Strategic Investment From Sanofi
1
$Ventyx Biosciences (VTYX.US)$
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease
Ventyx Biosciences (Nasdaq: VTYX) has initiated dosing in a Phase 2a trial of VTX3232 for early Parkinson's disease. The trial aims to evaluate the drug's effects on disease- and target-relevant biomarkers, including exploratory PET neuroimaging to measure its impact on microglial activation. This study is based on evidence suggesting a str...
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease
Ventyx Biosciences (Nasdaq: VTYX) has initiated dosing in a Phase 2a trial of VTX3232 for early Parkinson's disease. The trial aims to evaluate the drug's effects on disease- and target-relevant biomarkers, including exploratory PET neuroimaging to measure its impact on microglial activation. This study is based on evidence suggesting a str...
1
$Ventyx Biosciences (VTYX.US)$ Reuters· just
Ventyx Biosciences Inc - Vtx958 Phase 2 Trial Fails Primary Endpoint in Crohn's Disease
Ventyx Biosciences Inc - Vtx958 Phase 2 Trial Fails Primary Endpoint in Crohn's Disease
3
No comment yet
Tonyco OP : (all of them tank 30%, is murdered under mysterious circumstances days later)